| Literature DB >> 29171762 |
Radhika Radha Maniswami1, Seema Prashanth1, Archana Venkataramana Karanth1, Sindhu Koushik1, Hemalatha Govindaraj1, Ramesh Mullangi1, Sriram Rajagopal1, Sooriya Kumar Jegatheesan1.
Abstract
INTRODUCTION: Polo like kinase (PLK) is known to play a pivotal role in various cell cycle processes to perpetuate proper division and growth of the cells. Polo like kinase-4 (PLK4) is one such kinase that appears in low abundance and plays a well-characterized role in centriole duplication. PLK4 deregulation (i.e. both overexpression and depletion of PLK4), leads to altered mitotic fidelity and thereby triggers tumorigenesis. Hence, over the last few years PLK4 has emerged as a potential therapeutic target for the treatment of various advanced cancers. Areas covered: In this review, we discuss the basic structure, expression, localization and functions of PLK4 along with its regulation by various proteins. We also discuss the role of altered PLK4 activity in the onset of cancer and the current pre-clinical and clinical inhibitors to regulate PLK4. Expert opinion: PLK4 mediated centriole duplication has a crucial role in maintaining mitotic correctness in normal cells, while its deregulation has a greater impact on genesis of cancer. Henceforth, a deep knowledge of the PLK4 levels, its role and interactions with various proteins in cancer is required to design effective inhibitors for clinical use.Entities:
Keywords: 945; CFI-400; PLK4; centriole duplication
Mesh:
Substances:
Year: 2017 PMID: 29171762 DOI: 10.1080/14728222.2018.1410140
Source DB: PubMed Journal: Expert Opin Ther Targets ISSN: 1472-8222 Impact factor: 6.902